会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 골막으로부터 연골전구세포를 분리하는 방법
    • 用于从周期蛋白分离造血细胞的方法
    • KR1020070025607A
    • 2007-03-08
    • KR1020050081947
    • 2005-09-02
    • 보령제약 주식회사
    • 김동일임상민최용수이창우김상린단현광정한선
    • C12N5/071C12N5/07C12N5/00
    • A method for isolating chondroprogenitor cell from periosteum is provided to be able to obtain periosteum-derived chondroprogenitor cells using mesenchymal stem cell surface immune indicator and flow cytometry, which is successfully differentiated into cartilage cell used as a cartilage cell therapeutic agent. The method comprises the steps of: (a) after cutting periosteal tissue derived from mammals into fragments, culturing them to isolate cells from the periosteal tissue; (b) and isolating only cells which are positive to mesenchymal stem cell surface marker such as CD9, CD90 and CD116 and negative to hematopoietic stem cell surface marker such as CD45 from the cells isolated by the step(a). To differentiate the periosteum-derived chondroprogenitor cells into cartilage cells, the chondroprogenitor cells are pellet-cultured in a culture medium including TGF-beta3.
    • 提供了一种从骨膜中分离软骨祖细胞的方法,能够使用间充质干细胞表面免疫指示剂和流式细胞术获得骨膜来源的软骨祖细胞,其成功分化为用作软骨细胞治疗剂的软骨细胞。 该方法包括以下步骤:(a)将源自哺乳动物的骨膜组织切成碎片,培养它们以从骨膜组织中分离细胞; (b),并且仅从由步骤(a)分离的细胞中分离出对间充质干细胞表面标志物如CD9,CD90和CD116呈阳性的细胞,并将其分离为造血干细胞表面标志物例如CD45。 为了将骨膜衍生的软骨祖细胞分化为软骨细胞,将软骨祖细胞在包含TGF-β3的培养基中沉淀培养。
    • 3. 发明公开
    • 식물 세포배양에서 아미노산과 피루브산을 이용한 목적단백질의 생산 방법
    • 在植物细胞培养中使用氨基酸和吡啶酸生产目标蛋白的方法
    • KR1020080027729A
    • 2008-03-28
    • KR1020070095146
    • 2007-09-19
    • 보령제약 주식회사
    • 김상린단현광임상민류욱상정한선이송재박천익강승훈김동일
    • C12P21/04C12P21/00C12N5/04C12N15/82
    • C12P21/00A01H4/00C12N15/8237
    • A method for producing a target protein is provided to secure an optimized culture condition for enhancing the production yield of the target protein by inducing the protein expression without exchange of a cell growth medium with a sugar-free medium and addition of pyruvic acid during the induction period of protein expression, thereby mass-producing a recombinant protein. A method for producing a target protein by culturing a transgenic plant cell including a promoter expressing the protein without sugars and a gene encoding the target protein comprises the steps of: (a) culturing the transgenic plant cell in a sugar-rich medium to grow the pant cells; and (b) culturing the transgenic plant cells with addition of an amino acid mixture to the culture of step(a) without exchange of a cell growth medium with a sugar-depleted medium, wherein the target protein is a human CTLA4Ig, the promoter is an RAmy3D promoter of alpha-amylase and the plant cell is a rice cell. Further, the culture is fed-batch culture.
    • 提供靶蛋白的制造方法,以确保用于通过诱导蛋白质表达而不增加无糖培养基的细胞生长培养基和在诱导期间加入丙酮酸而提高靶蛋白的产量的优化培养条件 蛋白质表达时间,从而大量生产重组蛋白。 通过培养包含表达无糖蛋白的启动子的转基因植物细胞和编码靶蛋白的基因的转基因植物细胞的制备方法包括以下步骤:(a)在富糖培养基中培养转基因植物细胞以生长 裤细胞; 和(b)通过向步骤(a)的培养物中加入氨基酸混合物来培养转基因植物细胞,而不与不含糖的培养基交换细胞生长培养基,其中靶蛋白是人CTLA4Ig,启动子是 α-淀粉酶的RAmy3D启动子和植物细胞是水稻细胞。 此外,培养是补料分批培养。
    • 9. 发明公开
    • 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
    • 新化合物,其制备方法和包含抗血清药物的药物组合物
    • KR1020130013163A
    • 2013-02-06
    • KR1020110074638
    • 2011-07-27
    • 보령제약 주식회사
    • 김지한김제학이준광정한선한남석박용강승훈정희진이경태최혜은지용하이주한백수희
    • C07D213/82C07D401/12A61K31/444A61P35/00
    • C07D401/14C07D213/82C07D401/12C07D413/14C07D417/14C07D495/04
    • PURPOSE: A pharmaceutical composition containing a compound which suppresses angiogenesis is provided to prevent and treat diseases caused by angiogenesis suppression abnormality. CONSTITUTION: A compound which suppresses angiogenesis is denoted by chemical formula I. The compound of chemical formula I or pharmaceutically acceptable salts thereof is 2-(1-benzylpiperidine-4-ylamino)-N-(3-chlorphenyl)nicotiamide[103] or pharmaceutically acceptable salts thereof. A method or preparing the compound of chemical formula I comprises a step of reacting a compound of chemical formula II and a compound of chemical formula III under the presence of a base. The base is triethyl amine, N,N-diisopropylethyl amine, N-methylmorpholine, DBU(1,8-diazabicyclo[5.4.0]undec-7-ene), N-methylpiperidine, 4-dimethylaminopyridine, N,N-dimethylaniline, 2,6-lutidine, 4-N,N-dimethylaminopyridine, or pyridine. A pharmaceutical composition for preventing or treating diseases or symptoms caused by VEGF(Vascular Endothelial Growth Factor) abnormality contains the compound of chemical formula I or the salts.
    • 目的:提供含有抑制血管生成的化合物的药物组合物,用于预防和治疗由血管发生抑制异常引起的疾病。 构成:抑制血管发生的化合物由化学式I表示。化学式I化合物或其药学上可接受的盐是2-(1-苄基哌啶-4-基氨基)-N-(3-氯苯基)烟酰胺[103]或 其药学上可接受的盐。 制备化学式I化合物的方法包括使化学式II化合物与化学式III化合物在碱存在下反应的步骤。 碱为三乙胺,N,N-二异丙基乙胺,N-甲基吗啉,DBU(1,8-二氮杂双环[5.4.0]十一碳-7-烯),N-甲基哌啶,4-二甲基氨基吡啶,N,N-二甲基苯胺, 2,6-二甲基吡啶,4-N,N-二甲基氨基吡啶或吡啶。 用于预防或治疗由VEGF(血管内皮生长因子)异常引起的疾病或症状的药物组合物含有化学式I的化合物或其盐。